Secukinumab cost effective for active disease in UK

Secukinumab cost effective for active disease in UK PharmacoEconomics & Outcomes News 804, p31 - 2 Jun 2018 uncertainty in results in the biologic-naıve population. Secukinumab cost effective for "Even at list price, secukinumab appears to represent a active disease in UK cost-effective use of NHS resources for biologic-naıve and biologic-experienced patients with active AS," the Secukinumab appears to be cost effective in adults in authors concluded. "This research highlights a continued the UK with active psoriatic arthritis (PsA) and active need for longer-term data on all biologic treatments in ankylosing spondylitis (AS) with inadequate response to this indication to help inform future cost-effectiveness previous treatment, according to findings of two analyses," they said. Novartis-funded cost-utility studies published in 1,2 PharmacoEconomics. * 2017 British pounds ** nonsteroidal anti-inflammatory drugs and non-pharmacological Psoriatic arthritis interventions such as physiotherapy A 3-month decision tree leading into a Markov model 1. Buchanan V, et al. Cost Effectiveness of Secukinumab for the Treatment of populated with data from the FUTURE 2 trial and a Active Psoriatic Arthritis in the UK. PharmacoEconomics : 25 May 2018. network meta-analysis was used to evaluate the Available from: URL: https://doi.org/10.1007/s40273-018-0674-x. 2. Emery P, et al. Cost Effectiveness of Secukinumab for the Treatment of Active cost effectiveness of secukinumab compared with Ankylosing Spondylitis in the UK. PharmacoEconomics : 25 May 2018. tumour necrosis factor inhibitors (TNFis) or standard of Available from: URL: https://doi.org/10.1007/s40273-018-0675-9. care in adults with active PsA who were TNFi-naıve, had 803324247 no concomitant moderate-to-severe psoriasis, and had inadequate response to conventional systemic disease- modifying anti-rheumatic drugs (csDMARDs). Cost effectiveness was assessed from the UK National Health Service (NHS) perspective over a 40-year time horizon. The estimated incremental cost-effectiveness ratio (ICER) for secukinumab compared with standard of care was £28 748 per QALY gained in patients who had received one prior csDMARD. In patients who had received two or more prior csDMARDs, secukinumab dominated (more effective and less costly) certolizumab pegol, etanercept and golimumab, had an ICER of £5680 per QALY gained versus adalimumab and saved over £1 million per QALY foregone versus infliximab. At a willingness-to-pay threshold between £20 000 and £30 000 per QALY gained, secukinumab had 48.9% probability of having the highest net monetary benefit in patients who had received one prior csDMARD, and 88.9% probability in patients who had received two or more prior csDMARDs. "Secukinumab 150 mg at list price appears to represent a cost-effective use of NHS resources for adults with PsA who have responded inadequately to one or two or more prior csDMARDs," concluded the authors. Ankylosing spondylitis A 3-month decision tree leading into a Markov model populated with data from the MEASURE 1 and 2 trials was used to evaluate the cost effectiveness of secukinumab, compared with licensed TNFis including biosimilars, in adults with active AS who had not responded adequately to previous treatment with ** conventional care (biologic-naıve) or previous biologic therapy (biologic-experienced), from the perspective of the UK NHS over a 40-year (lifetime) time horizon. In the biologic-naıve population, secukinumab dominated adalimumab and certolizumab pegol. ICERs versus other comparators were either below £10 000 per QALY gained or south-west ICERs that implied that secukinumab was cost effectiveness. All interventions other than secukinumab, etanercept biosimilar and infliximab biosimilar were dominated or extendedly dominated. The ICER for secukinumab versus etanercept biosimilar was £7524 per QALY gained, and the ICER for infliximab biosimilar versus secukinumab was £657 820 per QALY gained. In biologic-experienced patients, the ICER for secukinumab versus conventional care was £4927 per QALY gained. Probabilistic sensitivity analysis identified 1173-5503/18/0804-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Jun 2018 No. 804 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Secukinumab cost effective for active disease in UK

Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/secukinumab-cost-effective-for-active-disease-in-uk-qMUJ45ZkfD
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-018-4995-y
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 804, p31 - 2 Jun 2018 uncertainty in results in the biologic-naıve population. Secukinumab cost effective for "Even at list price, secukinumab appears to represent a active disease in UK cost-effective use of NHS resources for biologic-naıve and biologic-experienced patients with active AS," the Secukinumab appears to be cost effective in adults in authors concluded. "This research highlights a continued the UK with active psoriatic arthritis (PsA) and active need for longer-term data on all biologic treatments in ankylosing spondylitis (AS) with inadequate response to this indication to help inform future cost-effectiveness previous treatment, according to findings of two analyses," they said. Novartis-funded cost-utility studies published in 1,2 PharmacoEconomics. * 2017 British pounds ** nonsteroidal anti-inflammatory drugs and non-pharmacological Psoriatic arthritis interventions such as physiotherapy A 3-month decision tree leading into a Markov model 1. Buchanan V, et al. Cost Effectiveness of Secukinumab for the Treatment of populated with data from the FUTURE 2 trial and a Active Psoriatic Arthritis in the UK. PharmacoEconomics : 25 May 2018. network meta-analysis was used to evaluate the Available from: URL: https://doi.org/10.1007/s40273-018-0674-x. 2. Emery P, et al. Cost Effectiveness of Secukinumab for the Treatment of Active cost effectiveness of secukinumab compared with Ankylosing Spondylitis in the UK. PharmacoEconomics : 25 May 2018. tumour necrosis factor inhibitors (TNFis) or standard of Available from: URL: https://doi.org/10.1007/s40273-018-0675-9. care in adults with active PsA who were TNFi-naıve, had 803324247 no concomitant moderate-to-severe psoriasis, and had inadequate response to conventional systemic disease- modifying anti-rheumatic drugs (csDMARDs). Cost effectiveness was assessed from the UK National Health Service (NHS) perspective over a 40-year time horizon. The estimated incremental cost-effectiveness ratio (ICER) for secukinumab compared with standard of care was £28 748 per QALY gained in patients who had received one prior csDMARD. In patients who had received two or more prior csDMARDs, secukinumab dominated (more effective and less costly) certolizumab pegol, etanercept and golimumab, had an ICER of £5680 per QALY gained versus adalimumab and saved over £1 million per QALY foregone versus infliximab. At a willingness-to-pay threshold between £20 000 and £30 000 per QALY gained, secukinumab had 48.9% probability of having the highest net monetary benefit in patients who had received one prior csDMARD, and 88.9% probability in patients who had received two or more prior csDMARDs. "Secukinumab 150 mg at list price appears to represent a cost-effective use of NHS resources for adults with PsA who have responded inadequately to one or two or more prior csDMARDs," concluded the authors. Ankylosing spondylitis A 3-month decision tree leading into a Markov model populated with data from the MEASURE 1 and 2 trials was used to evaluate the cost effectiveness of secukinumab, compared with licensed TNFis including biosimilars, in adults with active AS who had not responded adequately to previous treatment with ** conventional care (biologic-naıve) or previous biologic therapy (biologic-experienced), from the perspective of the UK NHS over a 40-year (lifetime) time horizon. In the biologic-naıve population, secukinumab dominated adalimumab and certolizumab pegol. ICERs versus other comparators were either below £10 000 per QALY gained or south-west ICERs that implied that secukinumab was cost effectiveness. All interventions other than secukinumab, etanercept biosimilar and infliximab biosimilar were dominated or extendedly dominated. The ICER for secukinumab versus etanercept biosimilar was £7524 per QALY gained, and the ICER for infliximab biosimilar versus secukinumab was £657 820 per QALY gained. In biologic-experienced patients, the ICER for secukinumab versus conventional care was £4927 per QALY gained. Probabilistic sensitivity analysis identified 1173-5503/18/0804-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Jun 2018 No. 804

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Jun 2, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off